Combining a peptide-based cancer vaccine with a viral vector boost converted immune-excluded cold tumors into hot, inflamed tumors and prolonged survival in mice.
Cold → Hot conversionThe peptide vaccine + viral vector boost recruited immune cells into previously immune-excluded TC-1 tumors, converting them from cold to hot — the key barrier to immunotherapy success
What the researchers found
A heterologous prime-boost vaccination strategy — combining a peptide-based vaccine (KISIMA-TAA) with a viral vector boost (VSV-GP-TAA) — generated potent antitumor immunity in two distinct mouse tumor models. In the cold TC-1 tumor model (HPV-associated), the combination turned immune-excluded tumors into hot, inflamed tumors by recruiting cross-presenting dendritic cells, increasing functional antigen-specific CD8+ killer T-cells, and polarizing CD4+ T-cells toward an antitumor Th1 phenotype.
In the already immune-infiltrated MC-38 model, the combination markedly prolonged overall survival. Multi-epitope vaccines induced high frequencies of T-cells targeting multiple tumor antigens simultaneously. The treatment also reduced immunosuppressive regulatory T-cells in tumors.
Why it matters
One of the biggest challenges in cancer immunotherapy is that many tumors are 'cold' — they exclude immune cells and don't respond to checkpoint inhibitors. This study shows that a peptide vaccine prime followed by a viral vector boost can convert cold tumors into hot, inflamed tumors susceptible to immune attack. If this approach translates to humans, it could extend the benefits of immunotherapy to the many cancer types that currently don't respond.
The numbers in context
2 tumor models tested · Cold TC-1 tumors converted to hot · MC-38 survival markedly prolonged · Cross-presenting DCs recruited · Tregs reduced · Multi-epitope antigen-specific responses induced
How the study worked
Mouse tumor models: TC-1 (cold, HPV antigen) and MC-38 (hot, neoantigen-expressing). Mice received a KISIMA peptide vaccine prime followed by VSV-GP viral vector boost, both expressing tumor-associated antigens. Immune cell profiling by flow cytometry analyzed dendritic cells, CD4+ and CD8+ T-cells, and regulatory T-cells in tumors and tumor-draining lymph nodes. Tumor growth and overall survival were measured.
Who was studied
Mice bearing TC-1 (cold, HPV) and MC-38 (hot, neoantigen) tumors
What this study cannot tell us
Mouse models only — TC-1 and MC-38 are well-characterized but don't represent the full complexity of human cancers. No comparison with checkpoint inhibitors alone was performed. The viral vector component introduces manufacturing complexity and potential safety considerations. Multi-epitope vaccine immunogenicity may differ in human HLA-diverse populations.
How to read the evidence
This is a preclinical animal study using two well-characterized mouse tumor models. The results are compelling across both cold and hot tumor settings, but translation to human cancers remains uncertain. Evidence strength is moderate — strong for preclinical proof-of-concept but without human data.
When this study was published
Published in 2021, this study provides the preclinical rationale for heterologous peptide vaccine + viral vector combination strategies that may now be entering human clinical trials.
The bigger picture
Converting cold tumors to hot is one of the most important unsolved problems in cancer immunotherapy. Checkpoint inhibitors like pembrolizumab and nivolumab work brilliantly in hot tumors but fail in cold ones — which represent the majority of solid tumors. This heterologous prime-boost strategy using peptide vaccines and viral vectors addresses this fundamental limitation. The multi-epitope approach, targeting multiple tumor antigens simultaneously, also reduces the risk of tumor immune escape. If validated in human trials, this could dramatically expand the population of cancer patients who benefit from immunotherapy.
Questions still open
- Will this heterologous prime-boost approach show similar cold-to-hot tumor conversion in human clinical trials?
- Could combining this peptide vaccine strategy with checkpoint inhibitors produce even greater antitumor effects?
- How will the neoantigen selection process work in human cancers where mutations vary widely between patients?
Common questions
What's the difference between a 'cold' and 'hot' tumor?
Why use two different types of vaccines (peptide + viral vector) instead of one?
Read the original research
Heterologous Prime-Boost Vaccination with a Peptide-Based Vaccine and Viral Vector Reshapes Dendritic Cell, CD4+ and CD8+ T Cell Phenotypes to Improve the Antitumor Therapeutic Effect.
Cancers, 13(23)
Citation
Hofer, Tamara; Rossi, Matteo; Carboni, Susanna; Di Berardino Besson, Wilma; von Laer, Dorothee; Wollmann, Guido; Derouazi, Madiha; Santiago-Raber, Marie-Laure. (2021). Heterologous Prime-Boost Vaccination with a Peptide-Based Vaccine and Viral Vector Reshapes Dendritic Cell, CD4+ and CD8+ T Cell Phenotypes to Improve the Antitumor Therapeutic Effect.. Cancers, 13(23). https://doi.org/10.3390/cancers13236107